STOCK TITAN

PureTech Health: Notice of Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announces plans to release its Annual Report and Accounts and financial results for the year ended December 31, 2023, on April 25, 2024. A presentation and conference call will follow to discuss the results.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) annuncia che pubblicherà il suo Rapporto Annuale e i risultati finanziari per l'anno concluso il 31 dicembre 2023, il 25 aprile 2024. Seguirà una presentazione e una conferenza telefonica per discutere i risultati.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) anuncia sus planes de publicar el Informe Anual y los resultados financieros del año que terminó el 31 de diciembre de 2023, el 25 de abril de 2024. Posteriormente, se realizará una presentación y una llamada de conferencia para discutir los resultados.
PureTech Health plc (나스닥: PRTC, LSE: PRTC)는 2023년 12월 31일로 끝나는 회계연도의 연간 보고서 및 재무 결과를 2024년 4월 25일에 발표할 계획을 발표했습니다. 결과에 대해 논의하기 위한 발표 및 컨퍼런스 콜이 이어질 예정입니다.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) annonce son intention de publier son Rapport Annuel et les résultats financiers pour l'année se terminant le 31 décembre 2023, le 25 avril 2024. Une présentation et une conférence téléphonique suivront pour discuter des résultats.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) kündigt an, seinen Jahresbericht und die Finanzergebnisse für das am 31. Dezember 2023 endende Jahr am 25. April 2024 zu veröffentlichen. Anschließend folgen eine Präsentation und eine Telefonkonferenz zur Erörterung der Ergebnisse.
Positive
  • None.
Negative
  • None.

BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2023, on Thursday, April 25, 2024.

A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations.

About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 28 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2022 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

PureTech

Public Relations

publicrelations@puretechhealth.com

Investor Relations

IR@puretechhealth.com

UK/EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

puretech@fticonsulting.com

U.S. Media

Nichole Bobbyn

+1 774 278 8273

nichole@tenbridgecommunications.com

Source: PureTech Health plc

PureTech Health will release its financial results on April 25, 2024.

The presentation and conference call will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication.

The webcast of the presentation will be available on PureTech Health's website at https://investors.puretechhealth.com/events-presentations.
PureTech Health plc American Depositary Shares

NASDAQ:PRTC

PRTC Rankings

PRTC Latest News

PRTC Stock Data

752.87M
154.84M
0.04%
0.02%
Investment Advice
Finance and Insurance
Link
United States of America
Boston

About PRTC

PureTech Health is a biotechnology company which develops medicines to combat serious diseases.